)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Kolon TissueGene
Kolon TissueGene (950160) investor relations material
Kolon TissueGene Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary14 Aug, 2026
Executive summary
Focus on cell and gene therapy platform (TG-C) for osteoarthritis, with U.S. Phase 3 clinical trials completed for knee OA and ongoing for other indications.
Revenue primarily from B2B technology licensing and distribution of health/beauty products; no commercial sales of TG-C yet.
Significant R&D investment, with pipeline expansion into hip OA, degenerative disc disease, and potential animal health applications.
Multiple legal proceedings related to past product issues and shareholder claims.
Financial highlights
2026 H1 revenue: $1.51M (down from $3.63M in 2025 H1); operating loss: $(8.47)M (improved from $(15.70)M in 2025 H1).
Net loss for 2026 H1: $(34.71)M; basic EPS: $(2.06).
Cash and equivalents: $43.8M; convertible bonds outstanding: $37.3M.
R&D expenses remain high, exceeding 2,100% of revenue.
Outlook and guidance
U.S. Phase 3 TG-C 15302 topline data released post-period; primary endpoint not met, further analysis ongoing.
TG-C 12301 study and follow-up analysis to inform future regulatory and commercialization strategy.
Pipeline expansion into hip OA and DDD continues, with additional clinical trials planned.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Kolon TissueGene
- TG-C advances toward FDA approval with strong clinical data and global commercialization plans.950160
Corporate presentation - Heavy R&D spending drives losses as Phase 3 knee OA trial completes and pipeline expands.950160Q3 2024
- Revenue up 31% but net loss deepens; Phase 3 knee OA trials completed, BLA submission ahead.950160Q4 2024
- Losses narrowed as Phase 3 TG-C trials completed dosing; focus remains on FDA approval.950160Q2 2024
- Phase 3 dosing for TG-C completed; losses persist, but cash position strengthened.950160Q1 2025
- 2025 net loss widened to $135.4M as TG-C phase 3 trials completed dosing; BLA filing planned.950160Q4 2025
- H1 2025 saw $1.83M revenue, $(44.2)M net loss, and high R&D costs amid pivotal TG-C trials.950160Q2 2025
- Heavy R&D spending and high leverage persist as FDA approval for TG-C becomes pivotal.950160Q1 2026
- TG-C Phase 3 completed; revenue down, net loss $(48.6)M, strong cash after capital raises.950160Q3 2025
Next Kolon TissueGene earnings date
Q3 202620 Nov, 2026
Kolon TissueGene
Next Kolon TissueGene earnings date
Q3 202620 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)